TL1A is encoded by TNFSF15 and is produced by endothelial cells. 5 Expression of TL1A can be induced in endothelial cells and chondrocytes under the influence of the inflammatory cytokines TNF and ...

TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.

周一，Leerink Partners开始对专注于开发癌症和炎症性疾病疗法的生物科技公司Shattuck Labs（NASDAQ:STTK）进行覆盖。该机构给予该股"优于大市"评级，目标价为4.00美元。根据InvestingPro数据显示，该股过去一年下跌超过86%，目前交易价格为1.19美元，显示出显著波动性。

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic inflammatory disease of the large intestine.

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...

At the recent 2025 congress of the European Crohn’s and Colitis Organisation, researchers from Helixon Therapeutics presented the discovery and preclinical characterization of HXN-1002, a bispecific ...

Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO. My name is Adam and I'll be your operator today. [Operator Instructions] I will now ...

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the ...

He contrasted this with AbbVie (NYSE:ABBV)’s pipeline, which lacks a TL1A molecule, and noted that Johnson & Johnson is conducting Phase 2 trials of a coformulated Tremfya + Simponi in UC and CD.